Uy Ear
Stock Analyst at Mizuho
(3.75)
# 757
Out of 5,005 analysts
69
Total ratings
43.9%
Success rate
12.7%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Outperform | $30 → $60 | $54.92 | +9.25% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $16.69 | +235.53% | 2 | Sep 24, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $21.80 | +10.09% | 14 | Aug 7, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $22.64 | -38.16% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $15.24 | +457.74% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $19.92 | +5.42% | 14 | Feb 26, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $2.32 | -56.90% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $31.06 | +28.78% | 5 | Nov 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $10.19 | +292.54% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $6.50 | +253.85% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $137.03 | +2.17% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $188.64 | -78.80% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.44 | +309.84% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.77 | +69.49% | 2 | Mar 1, 2023 |
uniQure
Sep 25, 2025
Maintains: Outperform
Price Target: $30 → $60
Current: $54.92
Upside: +9.25%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $16.69
Upside: +235.53%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $21.80
Upside: +10.09%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $22.64
Upside: -38.16%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $15.24
Upside: +457.74%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $19.92
Upside: +5.42%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $2.32
Upside: -56.90%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $31.06
Upside: +28.78%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $10.19
Upside: +292.54%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $6.50
Upside: +253.85%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $137.03
Upside: +2.17%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $188.64
Upside: -78.80%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.44
Upside: +309.84%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.77
Upside: +69.49%